Nazarov, A.Baquié, M.Nowak-Sliwinska, P.Zava, O.van Beijnum, J. R.Groessl, M.Chisholm, D. M.Ahmadi, Z.McIndoe, S. J.Griffioen, A. W.van den Bergh, H.Dyson, Paul Joseph2013-03-262013-03-262013-03-26201310.1038/srep01485https://infoscience.epfl.ch/handle/20.500.14299/90584New triruthenium-carbonyl clusters derivatized with glucose-modified bicyclophosphite ligands have been synthesized. These compounds were found to have cytostatic and cytotoxic activity and depending on the number of bicyclophosphite ligands, and could be tuned for either anti-cancer or specific anti-angiogenic activity. While some compounds had a broad cellular toxicity profile in several cell types others showed endothelial cell specific dose-dependent anti-proliferative and anti-migratory efficacy. A profound inhibition of angiogenesis was also observed in the in vivo chicken chorioallantoic membrane (CAM) model, and consequently, these new compounds have considerable potential in drug design, e.g. for the treatment of cancer.text::journal::journal article::research article